Skip to main content
Top

Open Access 08-04-2024 | Hepatitis C | Case Report

Reactivation of hepatitis C virus caused by steroid monotherapy for sudden deafness

Authors: Hiroki Kaneko, Yoshinori Ozono, Hisayoshi Iwakiri, Hiroshi Hatada, Naomi Uchiyama, Yuri Komaki, Kenichi Nakamura, Satoru Hasuike, Kenji Nagata, Hiroshi Kawakami

Published in: Clinical Journal of Gastroenterology

Login to get access

Abstract

Hepatitis C virus (HCV) reactivation has been reported to be caused due to several anticancer drugs and immunosuppressive agents; however, HCV reactivation after steroid monotherapy has rarely been reported. Here, we report the case of a 65-year-old Japanese man with HCV infection who developed HCV reactivation after the administration of prednisolone (PSL) for 6 days for sudden deafness. In the patient history, the positivity for anti-HCV antibody was observed, but serum level of HCV RNA was not measured. Two months after PSL administration, the patient experienced an alanine aminotransferase (ALT) flare and the serum level of HCV RNA was observed to be 6.2 log IU/mL; then, the patient was admitted to our hospital for hepatitis treatment. Based on the clinical course and laboratory findings, the patient was diagnosed with HCV reactivation. Although the ALT levels decreased spontaneously during follow-up, they did not drop to normal range; subsequently, sofosbuvir and ledipasvir treatments were started. A sustained virological response 24 weeks after the end of treatment was achieved. This case study suggests that HCV reactivation with hepatitis flare can occur even after a steroid monotherapy, and doctors should pay attention to HCV reactivation when administering PSL for patients with HCV infection.
Literature
2.
4.
go back to reference Komaki Y, Ozono Y, Nakamura K, et al. Efficacy and safety of glecaprevir and pibrentasvir in Japanese patients with hepatitis C virus infection aged 75 years or older. BMC Gastroenterol. 2022;22:210.CrossRefPubMedPubMedCentral Komaki Y, Ozono Y, Nakamura K, et al. Efficacy and safety of glecaprevir and pibrentasvir in Japanese patients with hepatitis C virus infection aged 75 years or older. BMC Gastroenterol. 2022;22:210.CrossRefPubMedPubMedCentral
5.
go back to reference Ozono Y, Nagata K, Hasuike S, et al. Efficacy and safety of sofosbuvir and ledipasvir in japanese patients aged 75 years or over with hepatitis C genotype 1. World J Hepatol. 2017;9:1340–5.CrossRefPubMedPubMedCentral Ozono Y, Nagata K, Hasuike S, et al. Efficacy and safety of sofosbuvir and ledipasvir in japanese patients aged 75 years or over with hepatitis C genotype 1. World J Hepatol. 2017;9:1340–5.CrossRefPubMedPubMedCentral
6.
go back to reference Kusumoto S, Tanaka Y, Suzuki R, et al. Monitoring of hepatitis B virus (HBV) DNA and risk of HBV reactivation in B-cell lymphoma: a prospective observational study. Clin Infect Dis. 2015;61:719–29.CrossRefPubMed Kusumoto S, Tanaka Y, Suzuki R, et al. Monitoring of hepatitis B virus (HBV) DNA and risk of HBV reactivation in B-cell lymphoma: a prospective observational study. Clin Infect Dis. 2015;61:719–29.CrossRefPubMed
7.
go back to reference Manzano-Alonso ML, Castellano-Tortajada G. Reactivation of hepatitis B virus infection after cytotoxic chemotherapy or immunosuppressive therapy. World J Gastroenterol. 2011;17:1531–7.CrossRefPubMedPubMedCentral Manzano-Alonso ML, Castellano-Tortajada G. Reactivation of hepatitis B virus infection after cytotoxic chemotherapy or immunosuppressive therapy. World J Gastroenterol. 2011;17:1531–7.CrossRefPubMedPubMedCentral
8.
go back to reference Inoue J, Nakamura T, Masamune A. Roles of Hepatitis B Virus Mutations in the Viral Reactivation after Immunosuppression Therapies. Viruses. 2019;11:457.CrossRefPubMedPubMedCentral Inoue J, Nakamura T, Masamune A. Roles of Hepatitis B Virus Mutations in the Viral Reactivation after Immunosuppression Therapies. Viruses. 2019;11:457.CrossRefPubMedPubMedCentral
9.
go back to reference European Association for the Study of the Liver. EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection. J Hepatol. 2017;67:370–98.CrossRef European Association for the Study of the Liver. EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection. J Hepatol. 2017;67:370–98.CrossRef
10.
go back to reference Terrault NA, Lok ASF, McMahon BJ, et al. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance. Hepatology. 2018;67:1560–99.CrossRefPubMed Terrault NA, Lok ASF, McMahon BJ, et al. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance. Hepatology. 2018;67:1560–99.CrossRefPubMed
11.
go back to reference Huang M, Huang L. Reactivation of hepatitis C viral infection after treatment with infliximab. J Clin Gastroenterol. 2014;48:189–90.CrossRefPubMed Huang M, Huang L. Reactivation of hepatitis C viral infection after treatment with infliximab. J Clin Gastroenterol. 2014;48:189–90.CrossRefPubMed
12.
go back to reference Torres HA, Davila M. Reactivation of hepatitis B virus and hepatitis C virus in patients with cancer. Nat Rev Clin Oncol. 2012;9:156–66.CrossRefPubMed Torres HA, Davila M. Reactivation of hepatitis B virus and hepatitis C virus in patients with cancer. Nat Rev Clin Oncol. 2012;9:156–66.CrossRefPubMed
13.
go back to reference Lok AS, Ward JW, Perrillo RP, et al. Reactivation of hepatitis B during immunosuppressive therapy: potentially fatal yet preventable. Ann Intern Med. 2012;156:743–5.CrossRefPubMedPubMedCentral Lok AS, Ward JW, Perrillo RP, et al. Reactivation of hepatitis B during immunosuppressive therapy: potentially fatal yet preventable. Ann Intern Med. 2012;156:743–5.CrossRefPubMedPubMedCentral
14.
go back to reference Torres HA, Hosry J, Mahale P, et al. Hepatitis C virus reactivation in patients receiving cancer treatment: a prospective observational study. Hepatology. 2018;67:36–47.CrossRefPubMed Torres HA, Hosry J, Mahale P, et al. Hepatitis C virus reactivation in patients receiving cancer treatment: a prospective observational study. Hepatology. 2018;67:36–47.CrossRefPubMed
15.
go back to reference Mahale P, Kontoyiannis DP, Chemaly RF, et al. Acute exacerbation and reactivation of chronic hepatitis C virus infection in cancer patients. J Hepatol. 2012;57:1177–85.CrossRefPubMed Mahale P, Kontoyiannis DP, Chemaly RF, et al. Acute exacerbation and reactivation of chronic hepatitis C virus infection in cancer patients. J Hepatol. 2012;57:1177–85.CrossRefPubMed
16.
go back to reference Lee HL, Bae SH, Jang B, et al. Reactivation of hepatitis C virus and its clinical outcomes in patients treated with systemic chemotherapy or immunosuppressive therapy. Gut Liver. 2017;11:870–7.CrossRefPubMedPubMedCentral Lee HL, Bae SH, Jang B, et al. Reactivation of hepatitis C virus and its clinical outcomes in patients treated with systemic chemotherapy or immunosuppressive therapy. Gut Liver. 2017;11:870–7.CrossRefPubMedPubMedCentral
17.
go back to reference Mahale P, Thomas SK, Kyvernitakis A, et al. Management of multiple myeloma complicated by hepatitis C virus reactivation: the role of new antiviral therapy. Open Forum Infect Dis. 2015;3:ofv211.CrossRefPubMedPubMedCentral Mahale P, Thomas SK, Kyvernitakis A, et al. Management of multiple myeloma complicated by hepatitis C virus reactivation: the role of new antiviral therapy. Open Forum Infect Dis. 2015;3:ofv211.CrossRefPubMedPubMedCentral
18.
go back to reference Tagawa A, Ogawa T, Tetsuka S, et al. Hepatitis C virus (HCV) reactivation during fingolimod treatment for relapsing and remitting multiple sclerosis. Mult Scler Relat Disord. 2016;9:155–7.CrossRefPubMed Tagawa A, Ogawa T, Tetsuka S, et al. Hepatitis C virus (HCV) reactivation during fingolimod treatment for relapsing and remitting multiple sclerosis. Mult Scler Relat Disord. 2016;9:155–7.CrossRefPubMed
19.
go back to reference Yazici O, Sendur MAN, Aksoy S. Hepatitis C virus reactivation in cancer patients in the era of targeted therapies. World J Gastroenterol. 2014;20:6716–24.CrossRefPubMedPubMedCentral Yazici O, Sendur MAN, Aksoy S. Hepatitis C virus reactivation in cancer patients in the era of targeted therapies. World J Gastroenterol. 2014;20:6716–24.CrossRefPubMedPubMedCentral
20.
go back to reference Lensen R, Netea MG, Rosendaal FR. Hepatitis C virus reactivation following COVID-19 vaccination – a case report. Int Med Case Rep J. 2021;14:573–6.PubMedPubMedCentral Lensen R, Netea MG, Rosendaal FR. Hepatitis C virus reactivation following COVID-19 vaccination – a case report. Int Med Case Rep J. 2021;14:573–6.PubMedPubMedCentral
21.
go back to reference Mori N, Imamura M, Takaki S, et al. Hepatitis C virus (HCV) reactivation caused by steroid therapy for dermatomyositis. Intern Med. 2014;53:2689–93.CrossRefPubMed Mori N, Imamura M, Takaki S, et al. Hepatitis C virus (HCV) reactivation caused by steroid therapy for dermatomyositis. Intern Med. 2014;53:2689–93.CrossRefPubMed
22.
go back to reference Sato K, Inoue J, Kakazu E, et al. Reactivation of hepatitis C virus with severe hepatitis flare during steroid administration for interstitial pneumonia. Clin J Gastroenterol. 2021;14:1221–6.CrossRefPubMed Sato K, Inoue J, Kakazu E, et al. Reactivation of hepatitis C virus with severe hepatitis flare during steroid administration for interstitial pneumonia. Clin J Gastroenterol. 2021;14:1221–6.CrossRefPubMed
23.
go back to reference Fontana RJ, Liou I, Reuben A, et al. AASLD practice guidance on drug, herbal, and dietary supplement-induced liver injury. Hepatology. 2023;77:1036–65.CrossRefPubMed Fontana RJ, Liou I, Reuben A, et al. AASLD practice guidance on drug, herbal, and dietary supplement-induced liver injury. Hepatology. 2023;77:1036–65.CrossRefPubMed
24.
25.
go back to reference Ciesek S, Steinmann E, Iken M, et al. Glucocorticosteroids increase cell entry by hepatitis C virus. Gastroenterology. 2010;138:1875–84.CrossRefPubMed Ciesek S, Steinmann E, Iken M, et al. Glucocorticosteroids increase cell entry by hepatitis C virus. Gastroenterology. 2010;138:1875–84.CrossRefPubMed
26.
go back to reference Magy N, Cribier B, Schmitt C, et al. Effects of corticosteroids on HCV infection. Int J Immunopharmacol. 1999;21:253–61.CrossRefPubMed Magy N, Cribier B, Schmitt C, et al. Effects of corticosteroids on HCV infection. Int J Immunopharmacol. 1999;21:253–61.CrossRefPubMed
27.
go back to reference Rumi MG, Filippi FDE, Vecchia CLA, et al. Hepatitis C reactivation in patients with chronic infection with genotypes 1b and 2c: a retrospective cohort study of 206 untreated patients. Gut. 2005;54:402–6.CrossRefPubMedPubMedCentral Rumi MG, Filippi FDE, Vecchia CLA, et al. Hepatitis C reactivation in patients with chronic infection with genotypes 1b and 2c: a retrospective cohort study of 206 untreated patients. Gut. 2005;54:402–6.CrossRefPubMedPubMedCentral
28.
go back to reference Pitini V, Sturniolo G, Arrigo C, et al. HCV genotype 2 as a risk factor for reactivation in patients with B-cell lymphoma undergoing rituximab combination chemotherapy. Br J Haematol. 2010;150:116–8.CrossRefPubMed Pitini V, Sturniolo G, Arrigo C, et al. HCV genotype 2 as a risk factor for reactivation in patients with B-cell lymphoma undergoing rituximab combination chemotherapy. Br J Haematol. 2010;150:116–8.CrossRefPubMed
29.
go back to reference Kawano Y, Miyanishi K, Takahashi S, et al. Hepatitis C virus reactivation due to antiemetic steroid therapy during treatment of hepatocellular carcinoma. J Infect Chemother. 2017;23:323–5.CrossRefPubMed Kawano Y, Miyanishi K, Takahashi S, et al. Hepatitis C virus reactivation due to antiemetic steroid therapy during treatment of hepatocellular carcinoma. J Infect Chemother. 2017;23:323–5.CrossRefPubMed
30.
go back to reference Brambilla S, Bellati G, Asti M, et al. Dynamics of hypervariable region 1 variation in hepatitis C virus infection and correlation with clinical and virological features of liver disease. Hepatology. 1998;27:1678–86.CrossRefPubMed Brambilla S, Bellati G, Asti M, et al. Dynamics of hypervariable region 1 variation in hepatitis C virus infection and correlation with clinical and virological features of liver disease. Hepatology. 1998;27:1678–86.CrossRefPubMed
31.
go back to reference Arcaini L, Merli M, Passamonti F, et al. Impact of treatment-related liver toxicity on the outcome of HCV-positive non-Hodgkin’s lymphomas. Am J Hematol. 2010;85:46–50.CrossRefPubMed Arcaini L, Merli M, Passamonti F, et al. Impact of treatment-related liver toxicity on the outcome of HCV-positive non-Hodgkin’s lymphomas. Am J Hematol. 2010;85:46–50.CrossRefPubMed
32.
go back to reference Coppola N, Pisaturo M, Guastafierro S, et al. Increased hepatitis C viral load and reactivation of liver disease in HCV RNA-positive patients with onco-haematological disease undergoing chemotherapy. Dig Liver Dis. 2012;44:49–54.CrossRefPubMed Coppola N, Pisaturo M, Guastafierro S, et al. Increased hepatitis C viral load and reactivation of liver disease in HCV RNA-positive patients with onco-haematological disease undergoing chemotherapy. Dig Liver Dis. 2012;44:49–54.CrossRefPubMed
Metadata
Title
Reactivation of hepatitis C virus caused by steroid monotherapy for sudden deafness
Authors
Hiroki Kaneko
Yoshinori Ozono
Hisayoshi Iwakiri
Hiroshi Hatada
Naomi Uchiyama
Yuri Komaki
Kenichi Nakamura
Satoru Hasuike
Kenji Nagata
Hiroshi Kawakami
Publication date
08-04-2024
Publisher
Springer Nature Singapore
Published in
Clinical Journal of Gastroenterology
Print ISSN: 1865-7257
Electronic ISSN: 1865-7265
DOI
https://doi.org/10.1007/s12328-024-01944-9
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.